Senator John Fetterman (D-PA) denounced activists seeking to expose the personal information of immigration enforcement personnel, calling the practice dangerous and unacceptable during a Sunday television appearance.
A 12-foot great white shark, tracked from Nova Scotia, has been detected in the Mississippi Sound, marking an unusual westward migration into the Gulf and offering clues about the region's marine health.
Elon Musk has issued a forceful rebuttal to allegations linking him to the late financier and convicted sex offender Jeffrey Epstein, following the release of emails showing past correspondence. The tech mogul asserts he is being unfairly targeted and positions himself as a champion for Epstein's victims.
Samsung Electronics has launched a special edition Galaxy Z Flip7 for the 2026 Winter Olympics, packed with AI-powered translation and athlete-centric features, while also previewing new on-screen privacy controls designed to thwart 'shoulder surfing'. These dual announcements underscore the tech giant's push to blend high-profile partnerships with user-centric innovation as it seeks to differentiate in a competitive market.
Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.
ArcBest (ARCB) presents a complex valuation picture, with a discounted cash flow model suggesting deep undervaluation while its P/E ratio signals potential overpricing. As the stock hovers around $90, investors weigh conflicting signals against a backdrop of shifting freight demand and industry consolidation.
Oracle Corp. plans a colossal $45-$50 billion capital raise in 2026 to expand its cloud infrastructure, aiming to meet surging demand from AI giants like OpenAI and Nvidia. The move comes as the company's aggressive data center spending pushes its free cash flow negative, a condition projected to last for years.
As artificial intelligence drives an unprecedented surge in electricity demand, one utility company—Constellation Energy—is uniquely positioned with its vast nuclear fleet to meet the need, turning an industry-wide bottleneck into a significant growth opportunity.
Asset managers ramped up bearish bets against the U.S. dollar to their highest level in months, only to be blindsided by a sudden rally fueled by speculation that former Fed Governor Kevin Warsh is President Trump's pick to lead the central bank.
The Northern Ireland Executive has suspended a planned revaluation of hotel business rates, averting significant tax increases for accommodation providers slated for 2026 and providing temporary stability for the region's tourism industry.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Goldcom's (GOLD) shares have soared nearly 90% in the past year, leaving investors to grapple with a critical question: has the market already priced in all the good news, or is there still room to run? A deep dive into the valuation metrics reveals a stark contradiction.
With shares of the global sustainability leader up nearly 7x over three years, investors are grappling with a critical question: has the market run too far ahead of fundamentals? A deep dive into valuation metrics suggests caution may be warranted.
Lantronix's new partnership to develop edge AI threat detection systems for drones has spotlighted the stock, but analysts are divided on whether its current valuation fully prices in the risks and opportunities of the nascent defense tech market.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Bayer's share price has more than doubled in the past 12 months, yet key valuation models suggest a significant gap remains between its market price and intrinsic value. We examine the metrics behind the rally and the lingering legal and portfolio challenges facing the company.
The home improvement giant is eliminating approximately 800 corporate positions and mandating a full-time return to office, while simultaneously launching new AI tools for professionals and expanding its organic seed offerings nationwide, signaling a dual focus on operational efficiency and future-facing customer engagement.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
While Boeing's Q4 revenue beat offers short-term relief, analysts point to its unprecedented order backlog as the true indicator of long-term recovery and growth potential in the commercial aviation sector.
As Smurfit Westrock navigates the complex post-merger landscape, its share price tells a conflicted story. While recent gains hint at optimism, a deeper look reveals a stock trading at a significant discount to some intrinsic value models, even as its P/E ratio suggests a premium. The market appears to be weighing integration execution risks against long-term synergy potential.
